Last reviewed · How we verify
NCT06095947
Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years
trial testing Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in GCP in 652 participants. Completed in 28 February 2023.
6 February 2023
Quick facts
| Lead sponsor | Hualan Biological Bacterin Co. Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 652 |
| Start date | 15 September 2021 |
| Primary completion | 6 February 2023 |
| Estimated completion | 28 February 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent — full drug profile →
Conditions studied
- GCP — all drugs for GCP →
Sponsor
Hualan Biological Bacterin Co. Ltd. — full company profile →
Who can join
Adults 3 to 8, any sex, with GCP. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this \[To evaluate the immunogenicity and safety of 1 - and 2-dose schedules of quadrivalent influenza vaccine (split virion) in healthy people with and without immunization history.\] is to \[aged 3-8 years\] in \[Healthy people\]. The main question\[s\] it aims to answer are: • \[To evaluate the immunogenicity of a two-dose schedule of quadrivalent influenza vaccine (quadrivalent influenza vaccine) in healthy population aged 3-8 years with or without vaccination history.\] •\[ To evaluate whether antibody levels are different 30 days after one dose of quadrivalent influenza vaccine versus two doses of quadrivalent influenza vaccine in healthy people aged 3-8 years with or without vaccination history.\]
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06095947
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Trials testing the same drug.
- NCT05431725 — Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent · Phase 3 · completed
Other Hualan Biological Bacterin Co. Ltd. trials
Trials by the same sponsor.
- NCT06334510 — Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations. · completed
- NCT03196661 — Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population · Phase 1 · completed
- NCT06177249 — To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell) · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06095947 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hualan Biological Bacterin Co. Ltd.
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06095947.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing